Received Sep 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | — | IM |
Had One Dose of Heplisav-B In June 2025, and Has Not Had Their Second Dose; Initial report received on 02-Sep-2025. A pharmacist reported that a patient received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and has not had the second dose. No medical history or concomitant medications were reported. In Jun-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC number, and site not available)] intramuscularly. At the time of this report on 02-Sep-2025, after receiving HEPLISAV-B, the patient has not had the second dose of HEPLISAV-B. The reporter noted that the patient will be given a different hepatitis B vaccine as the reporter's facility does not carry HEPLISAV-B. No other side effects were reported. Reporter declined to provide further information. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.